Campbell & Co Investment Adviser’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-350,891
Closed -$2.6M – 1248
2026
Q1
$2.6M Buy
+350,891
New +$3.69M 0.15% 204
2025
Q4
– Sell
-30,487
Closed -$235K – 1312
2025
Q3
$235K Sell
30,487
-46,288
-60% -$324K 0.02% 977
2025
Q2
$561K Buy
76,775
+56,739
+283% +$458K 0.04% 745
2025
Q1
$190K Buy
+20,036
New +$250K 0.01% 950
2024
Q4
– Sell
-20,264
Closed -$299K – 1260
2024
Q3
$299K Buy
+20,264
New +$317K 0.02% 905
2023
Q1
– Sell
-35,749
Closed -$330K – 956
2022
Q4
$330K Buy
+35,749
New +$333K 0.08% 511
2022
Q3
– Sell
-32,209
Closed -$263K – 850
2022
Q2
$263K Buy
+32,209
New +$308K 0.07% 510
2022
Q1
– Sell
-8,450
Closed -$288K – 829
2021
Q4
$288K Buy
+8,450
New +$331K 0.1% 375
2019
Q4
– Sell
-23,731
Closed -$454K – 778
2019
Q3
$454K Buy
23,731
+12,289
+107% +$288K 0.17% 214
2019
Q2
$251K Sell
11,442
-12,420
-52% -$273K 0.11% 382
2019
Q1
$488K Buy
+23,862
New +$415K 0.24% 127
2018
Q3
– Sell
-20,627
Closed -$270K – 477
2018
Q2
$270K Buy
20,627
+3,500
+20% +$38.5K 0.21% 233
2018
Q1
$140K Buy
17,127
+6,700
+64% +$54.3K 0.12% 328
2017
Q4
$92K Sell
10,427
-11,117
-52% -$103K 0.07% 370
2017
Q3
$240K Buy
21,544
+8,404
+64% +$81.8K 0.19% 233
2017
Q2
$118K Sell
13,140
-1,869
-12% -$14.8K 0.11% 298
2017
Q1
$118K Buy
15,009
+1,419
+10% +$11.6K 0.31% 134
2016
Q4
$116K Sell
13,590
-1,013
-7% -$8.68K 0.36% 117
2016
Q3
$120K Buy
14,603
+1,867
+15% +$15.7K 0.32% 126
2016
Q2
$102K Buy
+12,736
New +$102K 0.52% 73

Other funds holding NEO

Campbell & Co Investment Adviser's NEO Position: Q2 2026 in Review

Campbell & Co Investment Adviser sold out of NeoGenomics (NEO) in Q2 2026, closing a stake of 350,891 shares — an estimated $2.6M sold.

Campbell & Co Investment Adviser first reported a position in NEO in Q2 2016 and held it in 20 quarters. The position peaked at $2.6M in Q1 2026. 266 funds tracked by Wall St. Rank hold NEO as of Q2 2026.

  • Campbell & Co Investment Adviser reported no remaining NeoGenomics position as of Q2 2026 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 350,891 NeoGenomics shares in Q2 2026, an estimated $2.6M.
  • Campbell & Co Investment Adviser first reported a position in NeoGenomics in Q2 2016 and held it in 20 quarters.
  • Campbell & Co Investment Adviser's NeoGenomics position peaked at $2.6M in Q1 2026.
  • 266 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.